Zoetis Q3 2026 net income drops 18% to $591 million
ZTS•Zoetis’ third-quarter 2026 net income fell 18% to $591 million, and revenue declined to $2.39 billion. The company narrowed full-year revenue guidance to $9.22 billion–$9.32 billion and lowered reported diluted EPS guidance to $5.50–$5.60.
1. Quarterly results and outlook
Zoetis’ third-quarter 2026 net income fell 18% to $591 million, while revenue declined to $2.39 billion. U.S. companion animal revenue dropped 8% to $980 million, reflecting macro-driven price sensitivity, dermatology competitive pressure and generic competition. The company narrowed full-year 2026 revenue guidance to $9.22 billion–$9.32 billion and lowered reported diluted EPS guidance to $5.50–$5.60.
2. Product approval
Convenia RTU for Dogs received FDA approval in October, with availability to veterinarians expected in the first quarter of 2027.
